Company Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartere...
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Valuation
Price to Sales Ratio
57.91
Price to Book Ratio
5.45
Enterprise Value to EBITDA
-2.52
Enterprise Value to Sales
9.04
Efficiency
Total Asset Turnover
0.08
Liquidity
Current Ratio
7.74
Quick Ratio
7.74
Cash Ratio
7.43
Profitability
Gross Margin
89.86
Operating Margin
-471.34
Pretax Margin
-470.27
Net Margin
-458.94
Return on Assets
-37.30
Return on Equity
-43.32
Return on Total Capital
-43.60
Capital Structure
Total Debt to Total Assets
1.68
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Dinesh V. Patel | 62 | 2008 | President, CEO & Chief Financial Officer |
Mr. Asif Ali | 47 | 2022 | Chief Financial Officer & Executive Vice President |
Ms. Paula O’Connor | - | - | Senior Vice President-Clinical Development |
Dr. Mohammad Masjedizadeh | - | - | Chief Technical officer & Executive VP |
Dr. Arturo Molina | 62 | 2022 | Chief Medical Officer |
Insider Actions
11/16/2022 |
David Y. Liu Chief R&D Strategy Officer |
35,331 | Derivative/Non-derivative trans. at $4.21 per share. | 148,743 |
11/16/2022 |
David Y. Liu Chief R&D Strategy Officer |
35,656 | Derivative/Non-derivative trans. at $1.16 per share. | 41,360 |
11/16/2022 |
David Y. Liu Chief R&D Strategy Officer |
5,999 | Derivative/Non-derivative trans. at $1.89 per share. | 11,338 |
11/16/2022 |
David Y. Liu Chief R&D Strategy Officer |
9,726 | Derivative/Non-derivative trans. at $1.89 per share. | 18,382 |
11/16/2022 |
David Y. Liu Chief R&D Strategy Officer |
13,767 | Derivative/Non-derivative trans. at $0.87 per share. | 11,977 |
11/15/2022 |
Arturo Molina Chief Medical Officer |
21,250 | Award at $0 per share. | 0 |
08/23/2022 |
Dinesh V. Patel President and CEO; Director |
20,000 | Derivative/Non-derivative trans. at $4.21 per share. | 84,200 |
05/04/2022 |
Dinesh V. Patel President and CEO; Director |
15,742 | Derivative/Non-derivative trans. at $4.21 per share. | 66,273 |
05/03/2022 |
William D. Waddill Director |
12,000 | Derivative/Non-derivative trans. at $8.59 per share. | 103,080 |
04/26/2022 |
Dinesh V. Patel President and CEO; Director |
30,000 | Derivative/Non-derivative trans. at $4.21 per share. | 126,300 |
04/26/2022 |
Suneel Gupta Chief Development Officer |
40,000 | Derivative/Non-derivative trans. at $7.38 per share. | 295,200 |
04/18/2022 |
Asif Ali Chief Financial Officer |
13,750 | Award at $0 per share. | 0 |
04/14/2022 |
Dinesh V. Patel President and CEO; Director |
34,087 | Derivative/Non-derivative trans. at $1.89 per share. | 64,424 |
02/28/2022 |
Dinesh V. Patel President and CEO; Director |
4,648 | Derivative/Non-derivative trans. at $24.28 per share. | 112,853 |
02/28/2022 |
Suneel Gupta Chief Development Officer |
649 | Derivative/Non-derivative trans. at $24.28 per share. | 15,757 |
02/28/2022 |
David Y. Liu Chief R&D Strategy Officer |
2,119 | Derivative/Non-derivative trans. at $24.28 per share. | 51,449 |
02/15/2022 |
Dinesh V. Patel President and CEO; Director |
31,250 | Award at $0 per share. | 0 |
02/15/2022 |
Suneel Gupta Chief Development Officer |
12,500 | Award at $0 per share. | 0 |
02/15/2022 |
David Y. Liu Chief R&D Strategy Officer |
10,000 | Award at $0 per share. | 0 |
02/15/2022 |
Donald A. Kalkofen Chief Financial Officer |
7,500 | Award at $0 per share. | 0 |
MarketWatch News on PTGX
-
5 Biotech Stocks That Are Bucking the Selloff
- Barron's Online
-
Protagonist Therapeutics upgraded to overweight from neutral at J.P. Morgan
- Tomi Kilgore
-
Protagonist Therapeutics downgraded to neutral from overweight at J.P. Morgan
- Tomi Kilgore
-
Biotech stocks are a buy — especially these 18 picks
- Michael Brush
-
Protagonist Therapeutics initiated at overweight with $35 price target at JPMorgan
- Tonya Garcia
-
Protagonist Therapeutics stock price target raised to $29 vs. $13 at Instinet
- Ciara Linnane
-
Protagnoist Therapeutics stock price target raised to $17 from $11 at Stifel Nicolaus
- Tomi Kilgore
-
Protagonist Therapeutics upgraded to buy from hold at Stifel Nicolaus
- Tomi Kilgore
-
- Barron's Online
-
A Biotech Collapses: Is Buying Now ‘Futile’?
- Barrons Blogs
-
Protagonist Therapeutics started at buy with $32 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
- Barron's Online
Other News on PTGX
-
10-Q: PROTAGONIST THERAPEUTICS, INC
- Edgar Online - (EDG = 10Q, 10K)
-
10-Q: PROTAGONIST THERAPEUTICS, INC
- Edgar Online - (EDG = 10Q, 10K)
-
Protagonist: Too Many Red Flags
- Seeking Alpha
-
10-Q: PROTAGONIST THERAPEUTICS, INC
- Edgar Online - (EDG = 10Q, 10K)
-
FFIE, EVOK and ZY among mid-day movers
- Seeking Alpha
-
Banco Santander, Polaris, Redfin among premarket losers' pack
- Seeking Alpha
- Loading more headlines...